Stepwise Application of Urine Markers to Detect Tumor Recurrence in Patients Undergoing Surveillance for Non-Muscle-Invasive Bladder Cancer
Open Access
- 22 December 2014
- journal article
- research article
- Published by Wiley in Disease Markers
- Vol. 2014, 1-7
Abstract
Background. The optimal use of urine markers in the surveillance of non-muscle-invasive bladder cancer (NMIBC) remains unclear. Aim of the present study was to investigate the combined and stepwise use of the four most broadly available urine markers to detect tumor recurrence in patients undergoing surveillance of NMIBC.Patients and Methods. 483 patients with history of NMIBC were included. Cytology, UroVysion, fluorescence in situ hybridization (FISH), immunocytology (uCyt+), and NMP22 ELISA were performed before surveillance cystoscopy. Characteristics of single tests and combinations were assessed by contingency analysis.Results. 128 (26.5%) patients had evidence of tumor recurrence. Sensitivities and negative predictive values (NPVs) of the single tests ranged between 66.4–74.3 and 82.3–88.2%. Two-marker combinations showed sensitivities and NPVs of 80.5–89.8 and 89.5–91.2%. A stepwise application of the two-test combinations with highest accuracy (cytology and FISH; cytology and uCyt+; uCyt+ and FISH) showed NPVs for high-risk recurrences (G3/Cis/pT1) of 98.8, 98.8, and 99.1%, respectively.Conclusions. Combinations of cytology, FISH, immunocytology, and NMP22 show remarkable detection rates for recurrent NMIBC. Stepwise two-test combinations of cytology, FISH, and immunocytology have a low probability of missing a high-risk tumor. The high sensitivities may justify the use of these combinations in prospective studies assessing the use of urine markers to individualize intervals between cystoscopies during follow-up.Keywords
This publication has 26 references indexed in Scilit:
- Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivityBJU International, 2011
- Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinomaCancer Cytopathology, 2009
- Nuclear Matrix Protein 22 as Adjunct to Urine Cytology and Cystoscopy in Follow-up of Superficial TCC of Urinary BladderUrology, 2009
- UroVysion Compared with Cytology and Quantitative Cytology in the Surveillance of Non–Muscle-Invasive Bladder CancerEuropean Urology, 2007
- Variability in the Performance of Nuclear Matrix Protein 22 for the Detection of Bladder CancerJournal of Urology, 2006
- Multi‐target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancerInternational Journal of Cancer, 2006
- uCyt+ test: Alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinomaUrology, 2006
- uCyt+/ImmunoCyt™ in the detection of recurrent urothelial carcinomaCancer, 2006
- Review of the state of the art and recommendations of the Papanicolaou Society of Cytopathology for urinary cytology procedures and reporting : The Papanicolaou Society of Cytopathology Practice Guidelines Task ForceDiagnostic Cytopathology, 2003
- The Development of a Multitarget, Multicolor Fluorescence in Situ Hybridization Assay for the Detection of Urothelial Carcinoma in UrineThe Journal of Molecular Diagnostics, 2000